CoChat

Atorvastatin in Pulmonary Arterial Hypertension (APATH) study

Open access
Zeng, Wei-Jie, Xiong, Chang-Ming, Zhao, Lan, Shan, Guang-Liang, Liu, Zhi-Hong, Xue, Fang, Gu, Qing, Ni, Xin-Hai, Zhao, Zhi-Hui, Cheng, Xian-Sheng, Wilkins, Martin R., He, Jian-Guo · 2012 · European Respiratory Journal
Cited by 62

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Statins have been shown to both prevent and attenuate pulmonary hypertension in animal models. This study investigates the potential therapeutic benefits of atorvastatin as an affordable treatment for pulmonary hypertension patients. 220 patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) were randomised, double-blind, to receive atrovastatin 10 mg daily or matching placebo in addition to supportive care. At 6 months, 6-min walk distance decreased by 16.6 m in the atorvastatin group and 14.1 m in the placebo group. The mean placebo-corrected treatment effect was -2.5 m (95% CI: -38–33; p=0.96), based on intention to treat. A small nonsignificant increase in pulmonary vascular resistance and fall in cardiac output was seen in both treatment groups. There was no significant difference in the proportion of patients who improved, remained stable or showed a deterioration in World Health Organization functional class between atorvastatin and placebo treatments. Nine patients died in the atorvastatin group and 11 in the placebo group. Serum cholesterol levels fell significantly on atorvastatin treatment. Discontinuation rates were 23.2% and 26.9% on atorvastatin and placebo, respectively. Atorvastatin 10 mg daily has no beneficial effect on the natural history of PAH or CTEPH over 6 months.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/09031936.00149011

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 62

Metadata

Authors
Zeng, W.-J., Xiong, C.-M., Zhao, L., Shan, G.-L., Liu, Z.-H., Xue, F., Gu, Q., Ni, X.-H., Zhao, Z.-H., Cheng, X.-S., Wilkins, M. R., & He, J.-G.
Venue
European Respiratory Journal
Published
2012-02-23
Volume
40
Issue
1
Pages
67-74
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W1949536786
Cited by
62
References
2
FWCI
3.79
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atorvastatin in Pulmonary Arterial Hypertension (APATH) study. https://app.cochat.ai/papers/10.1183/09031936.00149011
The paper
Zeng, W.-J., Xiong, C.-M., Zhao, L., Shan, G.-L., Liu, Z.-H., Xue, F., Gu, Q., Ni, X.-H., Zhao, Z.-H., Cheng, X.-S., Wilkins, M. R., & He, J.-G. (2012). Atorvastatin in Pulmonary Arterial Hypertension (APATH) study. European Respiratory Journal. https://doi.org/10.1183/09031936.00149011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.